With TheracosBio green light, another SGLT2 inhibitor wades into diabetes arena

With TheracosBio green light, another SGLT2 inhibitor wades into diabetes arena

Source: 
Fierce Pharma
snippet: 

A little over a month after bexagliflozin’s approval to treat cats with diabetes, the drug has been cleared in humans.